Want to see EBS full AI Analyst Report?
Top Page
Emergent Biosolutions
(NYSE:EBS)
Select Model
Select Model
Rating:50Neutral
Price Target:
$7.50
▲(3.31% Upside)
Action:Reiterated
Date:08/06/26
The score reflects a company with improving revenue and still-positive free cash flow, but weighed down by renewed losses, higher leverage, and weakened forward guidance tied to intensifying naloxone competition and a major impairment. Technical signals also remain bearish-to-neutral with the stock trading below key moving averages.
Positive Factors
Positive free cash flow
Emergent generates positive operating and free cash flow despite a TTM net loss, providing durable internal funding to service debt, fund restructuring and support CDMO capacity. Positive FCF cushions liquidity needs and reduces near-term financing reliance, aiding multi-quarter stability.
Negative Factors
Naloxone market competition
New entrants and OTC shifts materially alter naloxone pricing dynamics and prescription volumes, creating structural revenue and margin pressure for NARCAN. Persistent price erosion reduces long-term commercial cash flows and undermines a formerly stable product franchise across multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive free cash flow
Emergent generates positive operating and free cash flow despite a TTM net loss, providing durable internal funding to service debt, fund restructuring and support CDMO capacity. Positive FCF cushions liquidity needs and reduces near-term financing reliance, aiding multi-quarter stability.
Read all positive factors
Emergent Biosolutions (EBS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$372.53M
Dividend YieldN/A
Average Volume (3M)864.70K
Price to Earnings (P/E)―
Beta (1Y)2.80
Revenue Growth-29.89%
EPS Growth93.33%
CountryUS
Employees900
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.44
Shares Outstanding51,596,294
10 Day Avg. Volume681,844
30 Day Avg. Volume864,696
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)1.27
Price to Sales (P/S)0.89
P/FCF Ratio4.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.00Price Target Upside65.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.33
Revenue Forecast (FY)$733.05M
Emergent Biosolutions Business Overview & Revenue Model
Company Description
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and n...
How the Company Makes Money
Emergent BioSolutions makes money primarily through (1) selling its owned medical countermeasure and specialty products and (2) providing manufacturing and related services to third parties.
1) Product sales (commercial and government-oriented)
-...
Emergent Biosolutions Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Neutral
The call reflected a balance of strong near-term operational execution and financial results—Q2 revenue and adjusted EBITDA materially exceeded expectations, driven by accelerated MCM deliveries and improved margins—alongside significant commercial headwinds in the naloxone business that prompted a $191M noncash impairment and a downward revision to full-year revenue and profitability guidance. Management is taking proactive restructuring and capital allocation actions (debt refinancing, share repurchases, $40M annualized cost-savings plan) to preserve liquidity and position the company for 2027, but the naloxone competitive dynamics and guidance cuts temper the otherwise strong quarter.Positive Updates
Q2 Revenue Beat
Second-quarter revenue of $234 million, materially above the prior guidance high end of $185 million; year-to-date revenue $390 million, up from $363 million year-over-year (+7.4%).
Negative Updates
Naloxone Competitive Pressure and Price Erosion
Two new naloxone entrants (4 mg OTC approved 06/16/2026 and a 10 mg prescription product launching Aug 2026) and more aggressive pricing have increased competitive intensity. Management expects additional price erosion and pressure on commercial naloxone volumes going forward.
Read all updates
Q2-2026 Updates
Positive
Negative
Q2 Revenue Beat
Second-quarter revenue of $234 million, materially above the prior guidance high end of $185 million; year-to-date revenue $390 million, up from $363 million year-over-year (+7.4%).
Read all positive updates
Company Guidance
Emergent revised full‑year 2026 guidance downward, lowering total revenue to $645–$675M (prior $720–$760M) and trimming adjusted EBITDA to $130–$150M (prior $155–$175M), while forecasting a GAAP net loss of $(245)–(225)M and adjusted net income of $10–$30M; adjusted gross margin is expected at 42%–44% and Q3 revenue is guided to $110–$130M. The update reflects increased competitive pressure in naloxone (NARCAN), a noncash NARCAN impairment of ~ $191M taken in Q2, and announced restructuring actions expected to yield ~ $40M of annualized savings (with ~ $11M of costs to achieve). For context, Q2 revenue was $234M and YTD revenue $390M, Q2 adjusted EBITDA was $97M (41% margin) and YTD adjusted EBITDA $132M (34% margin); Q2 adjusted gross margin was 58% (YTD 56%); quarter‑end cash was $140M with $190M total liquidity, gross debt $590M, net debt $450M (net leverage 1.9x), the company collected ~$145M of A/R in July, repurchased 1.1M shares for ~$9M in Q2 (YTD 1.9M for ~$18M, $37.5M remaining), and sold an underutilized building for roughly $6–6.4M.Emergent Biosolutions Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
55
Neutral
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 770.20M | 742.90M | 1.04B | 1.05B | 1.12B | 1.77B |
| Gross Profit | 380.50M | 350.60M | 375.40M | 360.00M | 473.00M | 793.20M |
| EBITDA | -23.70M | 240.40M | 53.40M | -47.00M | 15.70M | 504.20M |
| Net Income | -176.80M | 52.60M | -190.60M | -760.50M | -211.60M | 219.50M |
Balance Sheet | ||||||
| Total Assets | 1.12B | 1.32B | 1.39B | 1.82B | 3.17B | 2.96B |
| Cash, Cash Equivalents and Short-Term Investments | 139.70M | 205.40M | 99.50M | 111.70M | 642.60M | 576.30M |
| Total Debt | 581.80M | 572.10M | 676.10M | 860.20M | 1.43B | 871.00M |
| Total Liabilities | 775.40M | 796.00M | 906.90M | 1.17B | 1.78B | 1.35B |
| Stockholders Equity | 341.40M | 522.60M | 482.80M | 649.30M | 1.39B | 1.61B |
Cash Flow | ||||||
| Free Cash Flow | 13.60M | 156.80M | 35.80M | -257.90M | -149.90M | 96.10M |
| Operating Cash Flow | 25.40M | 170.60M | 58.70M | -206.30M | -34.10M | 321.10M |
| Investing Cash Flow | -62.00M | 69.40M | 125.20M | 212.30M | -381.30M | -225.00M |
| Financing Cash Flow | -174.80M | -136.60M | -190.00M | -535.70M | 481.20M | -141.00M |
Emergent Biosolutions Technical Analysis
Negative
7.26
Price Trends
7.95
Negative
8.14
Negative
9.56
Negative
Market Momentum
-0.34
Positive
20.01
Positive
57.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EBS, the sentiment is Negative. The current price of 7.26 is below the 20-day moving average (MA) of 7.44, below the 50-day MA of 7.95, and below the 200-day MA of 9.56, indicating a bearish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 20.01 is Positive, neither overbought nor oversold. The STOCH value of 57.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EBS.
Emergent Biosolutions Risk Analysis
Emergent Biosolutions disclosed 59 risk factors in its most recent earnings report. Emergent Biosolutions reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Emergent Biosolutions Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $1.80B | 19.28 | 17.32% | ― | 37.03% | ― | |
69 Neutral | $1.04B | 216.30 | 2.13% | ― | 4.57% | ― | |
67 Neutral | $879.21M | 11.66 | 10.23% | ― | -1.39% | -41.70% | |
56 Neutral | $234.54M | 11.42 | 10.62% | ― | -22.07% | -58.28% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | $372.53M | -42.47 | -1.59% | ― | -29.89% | 93.33% |
* General Sector Average
EBS
Emergent Biosolutions
5.31
-2.93
-35.56%
PCRX
Pacira Pharmaceuticals
25.58
1.81
7.61%
SIGA
SIGA Technologies
3.12
-4.44
-58.75%
ANIP
ANI Pharmaceuticals
82.63
13.62
19.74%
AMPH
Amphastar Pharmaceuticals
19.81
-1.81
-8.37%
Emergent Biosolutions Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Emergent BioSolutions Announces Restructuring Amid Turnaround Efforts
Negative
Aug 5, 2026
On August 5, 2026, Emergent BioSolutions reported second-quarter 2026 revenue of $234.3 million, up 66% year-on-year, alongside a net loss of $180.2 million driven largely by a $191.3 million non-cash impairment charge, while adjusted net income r...
Business Operations and Strategy
Emergent BioSolutions Secures New ACAM2000 Biodefense Contract
Positive
Jun 29, 2026
On June 26, 2026, Emergent BioSolutions received a $52.7 million contract modification from the U.S. Department of Health and Human Services’ ASPR, exercising Option Year 7 of its 10‑year ACAM2000 contract. The deal covers delivery of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.